Silence Therapeutics Jumps On Clinical Trials


(MENAFN- Baystreet) eGain to Show AI Capabilities Next Week

  • United Boosts Flights to Guam
  • Worksport Makes Small Gains on Forging Links with Auto Giants
  • Camber Dips on Positive Test Results
  • Warner Bros. Discovery's Stock Sinks On Quarterly Loss Previous Articles Subscribe to Get Small Cap News & Alerts Glenn Wilkin - Friday, February 23, 2024

    Silence Therapeutics Jumps on Clinical Trials

    Silence Therapeutics plc, (NASDAQ: SLN) shares moved higher Friday, as the experienced and innovative biotechnology company announced that the initiation by AstraZeneca of a phase 1 clinical trial of the first product candidate under its siRNA (short interfering RNA) collaboration, has triggered a $10.0 million milestone payment to Silence.

    “This represents the first clinical milestone under our collaboration with AstraZeneca and the third program to enter the clinic from our mRNAi GOLDTM platform,” said Silence CEO Craig Tooman.

    “This is a very exciting time for Silence as we are beginning to establish ourselves as a platform company progressing multiple clinical programs targeting both rare and common genetic diseases. In addition to this great achievement under our collaboration with AstraZeneca, we are also pleased with the continued advancement of our proprietary pipeline with encouraging clinical data now emerging from our zerlasiran program in high Lp(a) and divesiran program in polycythemia vera.”

    Under the agreement, AstraZeneca will pay Silence an option fee of $10 million for each selected target at the point of candidate nomination. The deal covers up to ten targets. For each target selected, Silence is eligible for up to $140 million in development milestones and up to $250 million in commercialization milestones as well as tiered royalties on net sales ranging from high single digit to low double digit.

    SLN shares gained 78 cents or 3.4%, to $23.85.





    • About Us
    • Contact Us
    • Advertise
    • License Our Content
    • Jobs
    • Disclaimer
    • Privacy Policy

    Copyright 1998 - 2024 Baystreet Media Corp. All rights reserved. Nasdaq Stocks: Information delayed 15 minutes. Non-Nasdaq Stocks: Information delayed 20 minutes. Bid and Ask quotation information for NYSE and AMEX securities is only available on a real time basis. Market Data is provided by QuoteMedia. Earnings by Zacks. Analyst Ratings by Zacks

    MENAFN23022024000212011056ID1107892531


  • Legal Disclaimer:
    MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.